In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...
The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...
Amid a steady advance of kidney-focused label expansions, Novartis’ Fabhalta is slowing its roll in a key potential autoimmune niche. | Amid a steady advance of kidney-focused label expansions, ...
The potential new indication could significantly expand Nubeqa's market, with the target population accounting for an estimated 15% of new prostate cancer diagnoses. (iStock/Getty Images Plus) Bayer’s ...
This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...
As a snarl of pharma-focused lawsuits from Texas Attorney General Ken Paxton play out, Gilead Sciences has worked out a deal to put its own litigation to bed. | As a snarl of pharma-focused lawsuits ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results